Panel Discussion: Phase 0 for Radiopharmaceuticals: Benefits & Risks
Time: 1:30 pm
day: Day 2 C&S Track Pm
Details:
- Showcasing various preclinical studies (in vitro and in vivo)
- Addressing different combination treatments of 177Lu-based radionuclide therapies and agents such as DNA damage repair inhibitors
- Discussing cellular mechanisms and how to use this knowledge to design future (clinical) combination studies
